Martin

• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu … Ended
  2023-507268-37-00 5 2024-07-29 Hereditary Angioedema
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended
  2023-503910-60-00 4 2024-03-05 Rheumatoid arthritis
• A Phase 2a Study to Evaluate Setanaxib in Patients with Alport Syndrome Ended
  2023-505292-73-00 4 2024-01-10 Alport syndrome
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended
  2024-512646-42-00 4 2023-06-27 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended
  2023-505904-41-00 5 2022-11-17 Hereditary Angioedema Type I or II
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)
• Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapy Ended
  2023-508840-22-00 5 2022-06-27 Atypical hemolytic uremic syndrome
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• Clinical Outcomes, Tolerability and Safety of Oral Pantoprazole in Pediatric Participants Ended
  2023-508770-28-00 4 2021-10-05 EROSIVE ESOPHAGITIS
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 5 2021-06-03 SARS-CoV II infection (Coronavirus disease)
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien … Ended
  2023-507415-35-00 5 2021-01-15 Psoriatic Arthritis
• A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Ped … Ended
  2023-504711-32-00 5 2015-11-24 Ulcerative Colitis

Showing 73–94 of 94 trials